Glaukos Announces Participation in Piper Jaffray Healthcare Conference
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Nov 14, 2018--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 10:00 a.m. EST in New York City.
A live audio webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com and will be archived for 90 days.
Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent inject®, measuring 0.36 mm long and 0.23 mm wide, is the smallest medical device ever approved by the FDA.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181114005215/en/
CONTACT: Glaukos Corporation
Director, Investor Relations, Corporate Strategy & Development
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: SURGERY HEALTH MEDICAL DEVICES OPTICAL PHARMACEUTICAL PROFESSIONAL SERVICES FINANCE
SOURCE: Glaukos Corporation
Copyright Business Wire 2018.
PUB: 11/14/2018 04:15 PM/DISC: 11/14/2018 04:15 PM